Results 61 to 70 of about 1,251,059 (351)

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Features and prognostic impact of distant metastases in 45 dogs with de novo stage IV cutaneous mast cell tumours: A prospective study [PDF]

, 2017
BACKGROUND: Distant metastases in dogs with cutaneous mast cell tumors (cMCT) are rare and incurable. The aims of this prospective study were to clarify the clinico-pathological features of stage IV cMCTs and to identify possible prognostic factors for ...
Amati, M., Dacasto, M., Dentini, A., Ferrari, R., Giantin, M., Laganga, P., Marconato, L., Pizzoni, S., Sabattini, S., Stefanello, D., Tortorella, G.   +10 more
core   +1 more source

Pancreatitis Can Present Like Cancer: Lymphoplasmacytic Sclerosing Pancreatitis in a Patient with a History of Gastric Carcinoma

European Journal of Case Reports in Internal Medicine, 2019
Autoimmune pancreatitis has been associated with many syndromes in the presence of increased immunoglobulin levels. IgG4 antibodies are elevated in the context of lymphoplasmacytic sclerosing pancreatitis associated with IgG4-related disease.
Susana Rocha Amaral, Luís Elvas, Tatiana Pereira, Gabriela Sousa, Paula Jacinto   +4 more
doaj   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

“Green oncology”: a new paradigm for medical oncology

Annals of Oncology, 2015
n ...
Porcile, G., Aitini, E., Bretti, S., Crispino, S., Oliani, C., Romizi, R., Cova, D., Savia, F., Clerico, M., Palazzo, S., Labianca, R., Adami, F.   +11 more
openaire   +3 more sources

Frontiers in Pigment Cell and Melanoma Research

, 2018
We identify emerging frontiers in clinical and basic research of melanocyte biology and its associated biomedical disciplines. We describe challenges and opportunities in clinical and basic research of normal and diseased melanocytes that impact current ...
Birlea, Stanca, Bosenberg, Marcus W., Box, Neil F., Brash, Douglas, Cassidy, Pamela B., Chen, Suzie, D'Orazio, John August, Filipp, Fabian V., Fujita, Mayumi, Goh, Boon-Kee, Herlyn, Meenhard, Indra, Arup K., Larue, Lionel, Leachman, Sancy A., Liu-Smith, Feng, Manga, Prashiela, Montoliu, Lluis, Norris, David A., Poole, Caroline Le, Shellman, Yiqun, Smalley, Keiran S. M., Spritz, Richard A., Sturm, Richard A., Swetter, Susan M., Terzian, Tamara, Wakamatsu, Kazumasa, Weber, Jeffrey S.   +26 more
core   +1 more source

GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. [PDF]

, 2019
We report graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) (a composite end point of survival without grade III-IV acute GVHD [aGVHD], systemic therapy-requiring chronic GVHD [cGVHD], or relapse) and cGVHD-free relapse-free survival ...
Abdel-Azim, Hisham, Ahmed, Ibrahim, Aljurf, Mahmoud, Alousi, Amin M., Arora, Mukta, Askar, Medhat, Auletta, Jeffery J., Bhatt, Vijaya, Bredeson, Christopher, Chhabra, Saurabh, Couriel, Daniel R., Diaz, Miguel Angel, Gadalla, Shahinaz, Gajewski, James, Gale, Robert Peter, Gergis, Usama, Hematti, Peiman, Hemmer, Michael T., Hildebrandt, Gerhard C., Holtan, Shernan G, Inamoto, Yoshihiro, Khandelwal, Pooja, Kitko, Carrie, MacMillan, Margaret L., Majhail, Navneet, Marks, David I., Mehta, Parinda, Mehta, Rohtesh S., Nishihori, Taiga, Olsson, Richard F., Pawarode, Attaphol, Pidala, Joseph, Prestidge, Tim, Qayed, Muna, Rangarajan, Hemalatha, Ringden, Olle, Saad, Ayman, Savani, Bipin N., Schultz, Kirk R., Seo, Sachiko, Shah, Ami, Shah, Niketa, Solh, Melhem, Spellman, Stephen R., Spitzer, Thomas, Szer, Jeffrey, Teshima, Takanori, Verdonck, Leo F, Wagner, John, Wang, Tao, Weisdorf, Daniel J., Williams, Kirsten M., Wirk, Baldeep, Yared, Jean A.   +53 more
core   +2 more sources

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

A 2009 survey of the Australasian clinical medical physics and biomedical engineering workforce [PDF]

, 2010
A survey of the Australasian clinical medical physics and biomedical engineering workforce was carried out in 2009 following on from a similar survey in 2006.
Round, W. Howell
core   +2 more sources

Motivational factors influencing the choice of oncology as a specialty among French medical students

BMC Medical Education
Background There is limited data regarding what motivations are behind the choice of oncology (both medical oncology and radiation oncology) as a specialty among medical students.
Nicolas Penel, Pierre-Yves Cren, Christophe Ducroq, Estelle M. N. Laurent, Gabriel Choukroun, Marc Hazzan, Dominique Crie   +6 more
doaj   +1 more source